Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR Exon 20 (Insertion) status confers therapeutic sensitivity to Amivantamab, Carboplatin, Pemetrexed in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.